ArticleJournal of gastrointestinal oncology2025
Establishment of a prognostic nomogram for intrahepatic cholangiocarcinoma patients receiving chemotherapy: a SEER-based study.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chemotherapy is an important treatment for intrahepatic cholangiocarcinoma (ICC) patients, but there is a lack of survival prediction models. This study aims to develop a nomogram to predict cancer-specific survival (CSS) in ICC patients receiving chemotherapy. Methods: A retrospective analysis was performed using data from the Surveillance, Epidemiology, and End Results (SEER) database involving 1,363 ICC patients who receiving chemotherapy between 2010 and 2019. The patients were randomly allocated in a 7:3 ratio to the training cohort and validation cohort. Cox proportional hazards regression analysis was employed to identify prognostic factors for nomogram construction. The accuracy of the model was assessed using the concordance index (C-index), area under the curve (AUC) value, and calibration curve. Additionally, decision curve analysis (DCA), net reclassification improvement (NRI), and integrated discrimination improvement (IDI) were utilized to evaluate the clinical value of the nomogram and to compare it with tumor staging based on American Joint Committee on Cancer (AJCC) criteria. Results: Multivariate Cox regression analysis selected seven variables to establish the nomogram. The C-index and AUC value indicate that the nomogram has high accuracy. The calibration curve shows good consistency between the actual observed values and the nomogram-predicted CSS. Meanwhile, DCA, NRI, and IDI demonstrate that the nomogram has significant clinical applicability compared to tumor staging based on AJCC criteria. Furthermore, a risk classification system with satisfactory ability to identify different-risk patients was established. Conclusions: We have developed a nomogram for predicting the prognosis of ICC patients receiving chemotherapy, which can effectively assess the prognosis of this patient population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.